Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Non-invasive Neurostimulation as a Tool for Diagnostics and Management for Neurodegenerative Diseases

NCT: NCT05326750 · RECRUITING

NCT IDNCT05326750
StatusRECRUITING
Start Date2022-11-21
Completion2032-07
SponsorKuopio University Hospital (OTHER)
First posted
Last updated

Brief Summary

Double blinded, sham-controlled, randomized trial on repeated transcranial alternating current brain stimulation (tACS) in neurodegenerative diseases. The investigators will evaluate whether a 4-times daily repeated stimulation with gamma tACS on the posterior parietal cortex can improve symptoms in patients with neurodegenerative diseases, including dementia with Lewy Bodies, Alzheimer's disease, idiopathic normal pressure hydrocephalus and Frontotemporal dementia.

Frequently Asked Questions

What is Non-invasive Neurostimulation as a Tool for Diagnostics and Management for Neurodegenerative Diseases?

Non-invasive Neurostimulation as a Tool for Diagnostics and Management for Neurodegenerative Diseases is a clinical trial registered under NCT05326750. Current status: RECRUITING.

What is the status of NCT05326750?

The current status of NCT05326750 (Non-invasive Neurostimulation as a Tool for Diagnostics and Management for Neurodegenerative Diseases) is: RECRUITING.

When did Non-invasive Neurostimulation as a Tool for Diagnostics and Management for Neurodegenerative Diseases start?

Non-invasive Neurostimulation as a Tool for Diagnostics and Management for Neurodegenerative Diseases started on 2022-11-21.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑